A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1748-717X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial) ; volume:13 ; number:1 ; day:20 ; month:8 ; year:2018 ; pages:1-7 ; date:12.2018
Radiation oncology ; 13, Heft 1 (20.8.2018), 1-7, 12.2018
- Urheber
-
Mercier, Carole
- Beteiligte Personen und Organisationen
-
Dirix, Piet
Meijnders, Paul
Vermeulen, Peter
Van Laere, Steven
Debois, Hilde
Huget, Philippe
Verellen, Dirk
SpringerLink (Online service)
- DOI
-
10.1186/s13014-018-1096-9
- URN
-
urn:nbn:de:101:1-2018101523325598373720
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mercier, Carole
- Dirix, Piet
- Meijnders, Paul
- Vermeulen, Peter
- Van Laere, Steven
- Debois, Hilde
- Huget, Philippe
- Verellen, Dirk
- SpringerLink (Online service)
Ähnliche Objekte (12)
Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine
A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma
Immunity-and-matrix-regulatory cells enhance cartilage regeneration for meniscus injuries: a phase I dose-escalation trial
Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer
DON in pediatric cerebral malaria, a phase I/IIA dose-escalation safety study: study protocol for a clinical trial
A dose-escalation clinical trial to evaluate the safety and immunogenicity of a replication-defective HIV-1 vaccine-HIVAX
What does a modified-Fibonacci dose-escalation actually correspond to?
Phase I dose-escalation oncology trials with sequential multiple schedules
PK/PD modeling supports the dose-escalation decision in VIKING
Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine
A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma
Immunity-and-matrix-regulatory cells enhance cartilage regeneration for meniscus injuries: a phase I dose-escalation trial
Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer
DON in pediatric cerebral malaria, a phase I/IIA dose-escalation safety study: study protocol for a clinical trial
A dose-escalation clinical trial to evaluate the safety and immunogenicity of a replication-defective HIV-1 vaccine-HIVAX
What does a modified-Fibonacci dose-escalation actually correspond to?
Phase I dose-escalation oncology trials with sequential multiple schedules
PK/PD modeling supports the dose-escalation decision in VIKING
Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine
A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma
Immunity-and-matrix-regulatory cells enhance cartilage regeneration for meniscus injuries: a phase I dose-escalation trial
Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer
DON in pediatric cerebral malaria, a phase I/IIA dose-escalation safety study: study protocol for a clinical trial
A dose-escalation clinical trial to evaluate the safety and immunogenicity of a replication-defective HIV-1 vaccine-HIVAX
What does a modified-Fibonacci dose-escalation actually correspond to?
Phase I dose-escalation oncology trials with sequential multiple schedules